Objective To evaluate the effect of intracoronary anisodamine to correct the no-reflow phenomenon during AMI on no-reflow minipig model made by superselective LAD with 4F catheter then injection of micro thrombus.
Method 14 no-reflow minipig models were randomised to intracoronary saline (4 ml), diltiazem (1 mg diluted to 4 ml) and anisodamine (2 mg to 4 ml) groups. CAG was performed at 1, 3, 5, 10th minute after intracoronary injection. Corrected TIMI frame count and coronary artery diameter were obtained by QCA, meanwhile ECG and homodynamic parameters (HR, LVEDP, intracoronary MAP,) were recorded.
Results The corrected TIMI frame count in Anisodamine group was significantly decreased by 13.2%, 25.3%, 35.6%, 33.6% at 1, 3, 5, 10th minute compared with saline group, while decreased by 10.6%, 20.4%, 14.3%, 21.5% at 1, 3, 5, 10th minute compared with diltiazem group, (respectively). The medial LAD diameter in Anisodamine group increased from 2.12±0.38 mm to 2.60±0.43 mm (p<0.05) while to 2.51±0.42 mm in diltiazem group as compared before (p<0.05). HR and intracoronary MAP were increased and LVEDP reduced at 1, 3, 5, 10th minute after administration of anisodamine, which had significance compared with group NS (125±20 vs 140±25 bpm, 95±12 vs 126±13 mm Hg, p<0.05), accompanied with HR increasing (p<0.05). It was very important that no serious side effect and toxic reaction were found.
Conclusions Intracoronary anisodamine might reduce and correct the no-reflow phenomenon after PCI-AMI with the dilation of coronary vessel and homodynamic improvement, as well as no serious side effect and toxic reaction.